Related Experiment Videos
Combined therapy for angioimmunoproliferative lesions
A Avilés1, S Delgado, A Fernández
1Department of Hematology, Oncology Hospital, National Medical Center, México, D.F.
European Journal of Cancer. Part B, Oral Oncology
|September 1, 1994
Summary
Combined therapy, including radiotherapy and chemotherapy (cyclophosphamide, epirubin, vincristine, prednisone, and bleomycin), shows high efficacy for angioimmunoproliferative lesions (AIL). This approach achieved a 95% complete response rate in a prospective clinical trial.
Area of Science:
- Oncology
- Hematology
- Clinical Therapeutics
Background:
- Angioimmunoproliferative lesions (AIL) represent a challenging diagnosis with controversial treatment options.
- Evaluating novel therapeutic strategies is crucial for improving patient outcomes in malignant lymphoma.
Purpose of the Study:
- To assess the efficacy and safety of a combined therapeutic approach for angioimmunoproliferative lesions (AIL).
- To establish combined therapy as a primary treatment modality for AIL.
Main Methods:
- A prospective clinical trial involving 43 patients diagnosed with AIL.
- Treatment regimen included involved field radiotherapy (40-55 Gy) followed by six cycles of CEOP-Bleo chemotherapy (cyclophosphamide, epirubin, vincristine, prednisone, bleomycin).
Main Results:
- A complete response rate of 95% (41 out of 43 patients) was achieved.
- At a median follow-up of 40 months, 91% (40 patients) remained in complete remission.
- Treatment was generally well-tolerated, with two deaths attributed to sepsis and tumor progression during radiotherapy.
Conclusions:
- Combined radiotherapy and chemotherapy (CEOP-Bleo) demonstrate significant effectiveness as a primary treatment for AIL.
- This multimodal approach appears to be the optimal therapeutic strategy for patients with this malignant lymphoma.
- Further research is warranted to solidify the role of combined therapy in AIL management.